KMT2A and acute myeloid leukemia: Our results suggest inhibiting TRIAD1-substrate RTKs (with nintedanib) substitutes, to some extent, for increased TRIAD1 expression to normalize emergency granulopoiesis in MLL1-ELL-AML.